Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 63.76
-0.27 (-0.42%)
Apr 29, 2026, 3:00 PM CST
SHA:688513 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 263.81 | 273.57 | 238.23 | 226.57 | 246.52 | 232.43 | Upgrade
|
| Depreciation & Amortization | 92.61 | 92.61 | 81.37 | 73.23 | 58.35 | 32.6 | Upgrade
|
| Other Amortization | 1.52 | 1.52 | 3.14 | 1.49 | 1.34 | 1.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.03 | -0.03 | 0 | -0.13 | -0.26 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | -12.55 | -12.55 | 0.11 | 0.11 | 0.07 | 0.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | -39.01 | -39.01 | -24.76 | -25.48 | -27.84 | -42.04 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 3.03 | -0.36 | 1.42 | -2.25 | Upgrade
|
| Other Operating Activities | 58.65 | 2.3 | 9.34 | 6.12 | 4.81 | 2.24 | Upgrade
|
| Change in Accounts Receivable | -23.86 | -23.86 | -112.44 | -75.72 | -51.53 | -181.32 | Upgrade
|
| Change in Inventory | -38.71 | -38.71 | -34.8 | -22.74 | -39.5 | -21.55 | Upgrade
|
| Change in Accounts Payable | 6.96 | 6.96 | 82.73 | 90.2 | -45.57 | 129.14 | Upgrade
|
| Change in Other Net Operating Assets | 11.59 | 11.59 | 19.98 | 1.23 | -0.06 | 0.39 | Upgrade
|
| Operating Cash Flow | 311.54 | 264.94 | 263.24 | 275.25 | 151.94 | 147.6 | Upgrade
|
| Operating Cash Flow Growth | 29.64% | 0.65% | -4.36% | 81.15% | 2.95% | -5.70% | Upgrade
|
| Capital Expenditures | -91.08 | -86.28 | -117.42 | -175.26 | -339.33 | -270.19 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.44 | 0.41 | 0.49 | 0.26 | 0.33 | - | Upgrade
|
| Investment in Securities | -25.68 | -19.68 | 313.56 | -234.53 | -81.41 | 160.61 | Upgrade
|
| Other Investing Activities | -252.44 | -260.9 | - | -0.65 | 14.71 | -1.01 | Upgrade
|
| Investing Cash Flow | -368.76 | -366.45 | 196.63 | -410.17 | -405.7 | -110.59 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 30 | Upgrade
|
| Long-Term Debt Issued | - | 55 | 150 | 235 | 100 | - | Upgrade
|
| Total Debt Issued | 45 | 55 | 150 | 235 | 100 | 30 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -50 | Upgrade
|
| Long-Term Debt Repaid | - | -73.67 | -253.92 | -91.48 | -50 | - | Upgrade
|
| Total Debt Repaid | -83.67 | -73.67 | -253.92 | -91.48 | -50 | -50 | Upgrade
|
| Net Debt Issued (Repaid) | -38.67 | -18.67 | -103.92 | 143.52 | 50 | -20 | Upgrade
|
| Issuance of Common Stock | 9.54 | 9.54 | 34.76 | - | - | - | Upgrade
|
| Common Dividends Paid | -76.52 | -76.79 | -74.11 | -71.08 | -96.05 | -36.4 | Upgrade
|
| Other Financing Activities | -15.09 | 59.6 | -118.99 | 8.22 | 85.74 | - | Upgrade
|
| Financing Cash Flow | -120.74 | -26.32 | -262.27 | 80.67 | 39.7 | -56.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.91 | -0.47 | 0.03 | -0.07 | 0.02 | -0.01 | Upgrade
|
| Net Cash Flow | -178.87 | -128.3 | 197.64 | -54.32 | -214.04 | -19.39 | Upgrade
|
| Free Cash Flow | 220.46 | 178.66 | 145.82 | 99.99 | -187.38 | -122.59 | Upgrade
|
| Free Cash Flow Growth | 45.10% | 22.52% | 45.83% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 16.31% | 13.42% | 10.80% | 8.95% | -16.01% | -11.98% | Upgrade
|
| Free Cash Flow Per Share | 1.27 | 1.02 | 0.83 | 0.56 | -1.06 | -0.70 | Upgrade
|
| Cash Income Tax Paid | 168.36 | 154.87 | 147.05 | 91.73 | 108.05 | 118.32 | Upgrade
|
| Levered Free Cash Flow | 176.41 | 137.29 | -13.92 | 47.75 | -258.5 | -90.64 | Upgrade
|
| Unlevered Free Cash Flow | 176.41 | 137.29 | -11.62 | 49.89 | -256.87 | -90.41 | Upgrade
|
| Change in Working Capital | -53.48 | -53.48 | -47.22 | -6.3 | -132.46 | -76.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.